<DOC>
	<DOCNO>NCT02157701</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , study subject exercise-related knee pain/discomfort determine efficacy polyherbal capsule compare placebo capsule improve exercise capacity overall parameter joint health .</brief_summary>
	<brief_title>Polyherbal Capsule Formulation Joint Health</brief_title>
	<detailed_description>Subjects come study site Visit 1 screen assessment ( occur within 14 day start run-in period ) answer question associate habitual diet , exercise capacity , level activity . Those subject meet initial inclusion/exclusion criterion undergo run-in period least 7 day home discontinue use concurrent dietary supplement . Subjects return study site Visit 2 ( Baseline ; Day 0 ) assessment meet inclusion/exclusion criterion enrol study randomly assign study product . Approximately 108 subject ( 54 per treatment group ) enrol study . Subjects evaluate Visit 3 ( Day 14 ) , Visit 4 ( Day 45 ) , Visit 5 ( Day 60 , phone call ) , Visit 6 ( Day 90 ) . Exercise capacity ( ie , 6-minute time walk distance test ) assess , along overall knee wellness joint-related symptom use WOMAC , PGA , Knee Pain Rating Scale , rescue medication usage . Safety assess collect adverse event ( AEs ) clinical laboratory data .</detailed_description>
	<criteria>≥ 25 ≤ 75 year age history joint discomfort least 1 knee follow daily activity otherwise healthy body mass index ( BMI ) ≥ 25 ≤ 40 kg/m2 sum ≥ 60 mm ( base 100mm visual analog scale [ VAS ] ) first 2 question ( ie , `` How much pain walk flat surface ? '' `` How much pain go stair ? '' ) WOMAC ( Section A ; Appendix 2 ) female child bear potential must agree use appropriate birth control method entire study period agree initiate new exercise diet program entire study period agree change current diet exercise program , use dietary supplement test product , entire study period understand study procedure sign form provide informed consent participate study , authorize release relevant protect health information study investigator . use NSAIDS study ( however 81 mg aspirin daily cardioprotection allow ) daily use dietary supplement herbal supplement begin screen visit study subject history chronic inflammatory disease , immune system disorder autoimmune disorder include limited following : AIDS/HIV , ankylose spondylitis , dermatomyositis , fibromyalgia , Grave 's disease , Hashimoto 's thyroiditis , lupus , multiple sclerosis , myasthenia gravis , pernicious anemia , systemic vasculitis condition temporal arteritis , primary biliary cirrhosis , psoriasis , Raynaud 's syndrome , rheumatoid arthritis , sarcoidosis , scleroderma include CREST syndrome subset , Sjogren 's syndrome , temporal arteritis , inflammatory bowel disease , vitiligo , chronic infection Lyme disease , tuberculosis , endocarditis , osteomyelitis ; history current diagnosis gout pseudogout use immunosuppressive drug biologic product last 12 month ( include steroid [ except inhaled topical dose form ] ) antibiotic use , anticoagulant , intraarticular steroid past 3 month intraarticular hyaluronic acid past 6 month subject chronic pain syndrome judgment Investigator unlikely respond therapy ( Note chronic depression chronic anxiety know magnifier chronic pain syndrome also exclusionary . Chronic fatigue syndrome overlap chronic pain domain also exclusionary . In addition , fibromyalgia central nervous system ( CNS ) disorder overlap chronic pain chronic fatigue domain exclusionary well . ) significant GI condition would potentially interfere evaluation study product include limited inflammatory bowel disease ( ulcerative colitis Crohn 's ) , history lap band surgery , history perforation stomach intestine , gastroparesis clinically significant renal , hepatic , GI , endocrine ( include diabetes mellitus ) , neurologic ( particularly balance neuropathy problem ) , hematologic disorder ; chronic obstructive pulmonary disease ( COPD ) , asthma , lung disease , heart disease limit exercise capacity ( peripheral artery disease , ischemic heart disease , heart failure , stroke last year , uncontrolled hypertension [ systolic blood pressure 140 mmHg and/or diastolic 90 mmHg ] ) cause abnormal respiratory cardiovascular response 6minute time walk distance test ( angina arrhythmia ) know allergy sensitivity herbal ingredient test product , acetaminophen , olive oil , soy history presence cancer last 5 year ( except basal cell carcinoma skin insitu cervical cancer ) recent history ( within 2 year ) alcohol substance abuse participation clinical study exposure nonregistered drug product within 30 day prior study individual condition Investigator believe would interfere ability provide inform consent , comply study protocol , might confound interpretation study result put person undue risk , include subject bed wheelchairbound physical disability could interfere ability walk perform exercise capacity assessment include protocol ( eg , history knee hip joint replacement surgery ) diabetes control medication untreated unstable thyroid dysfunction ( hyper hypothyroidism ) subject significant mental health disorder ( bipolar disorder , chronic depression require medication , chronic anxiety disorder , obsessive compulsive disorder , active eating disorder include anorexia nervosa bulimia ) subject history seizure last 5 year dizziness exercise knee arthroscopy previous year surgery lumbar spine , hip , knee , ankle foot surgery schedule prior study completion pregnant lactate woman walk &gt; 575 meter ( 1886 foot ) , Knee Pain Rating Scale ( Appendix 4 ) score &lt; 40 mm 100 mm VAS assess knee discomfort , 6minute time walk distance test .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Dietary herb</keyword>
	<keyword>Polyherbal capsule</keyword>
	<keyword>Functional exercise capacity</keyword>
	<keyword>Joint health</keyword>
</DOC>